Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...
VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an ...
The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of ...
Akeso Biopharma, is pleased to announce that Dr. Michelle Xia , the company's founder, chairwoman, president, and CEO, will ...
Actinium Pharmaceuticals ( (ATNM) ) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, ...
The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cancers irrespective of the organ of ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback